Molecular targeting of CFTR as a therapeutic approach to cystic fibrosis
- 1 July 2007
- journal article
- review article
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 28 (7) , 334-341
Abstract
No abstract availableKeywords
This publication has 60 references indexed in Scilit:
- Revertant mutants G550E and 4RK rescue cystic fibrosis mutants in the first nucleotide-binding domain of CFTR by different mechanismsProceedings of the National Academy of Sciences, 2006
- Gene therapy progress and prospects: cystic fibrosisGene Therapy, 2006
- Rescue of ΔF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small moleculesAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2006
- Therapy through chaperones: Sense or antisense? Cystic fibrosis as a model diseaseJournal of Inherited Metabolic Disease, 2006
- Rescue of functional delF508‐CFTR channels in cystic fibrosis epithelial cells by the α‐glucosidase inhibitor miglustatFEBS Letters, 2006
- Small-molecule correctors of defective F508-CFTR cellular processing identified by high-throughput screeningJournal of Clinical Investigation, 2005
- Cystic FibrosisNew England Journal of Medicine, 2005
- Processing of CFTR: Traversing the cellular maze—How much CFTR needs to go through to avoid cystic fibrosis?Pediatric Pulmonology, 2005
- Systems biology in drug discoveryNature Biotechnology, 2004
- Phenanthrolines – a new class of CFTR chloride channel openersBritish Journal of Pharmacology, 2001